Sacituzumab govitecan and lung cancer

The medicine combines a laboratory-made antibody with a chemotherapy drug. The antibody seeks a marker on cancer cells and helps deliver the drug into the cell. Whether this approach is suitable depends on the type and stage of lung cancer, earlier treatments, test results, and local prescribing practice.

Your oncology team may review genomic tumour profiling when looking for changes that could influence treatment choices. Sacituzumab govitecan is given by infusion, with clinical checks and blood tests used to assess blood counts, liver function, symptoms, and response.

Give your team a complete list of medicines, supplements, allergies, previous cancer treatments, and health conditions. Ask how infusion visits are organised and which side effects should be reported between visits. Nausea, diarrhoea, tiredness, reduced blood-cell counts, hair loss, and infusion reactions can occur; your team can offer prevention or treatment for some effects.

Treatment planning may also involve chemotherapy, radiotherapy, surgery such as lung lobectomy, or palliative care, depending on the cancer's location, spread, symptoms, and goals. If cancer has spread to the brain, ask how brain imaging and symptom control fit into the plan.

Call your oncology team urgently for fever, chills, severe diarrhoea, repeated vomiting, unusual bleeding, marked weakness, or signs of infection. Seek emergency help for trouble breathing, chest pressure, fainting, facial swelling, or sudden confusion. Report a new hoarse voice, worsening cough, or rapidly changing symptoms rather than waiting for the next infusion.

Ask why this medicine is being considered, what testing supports the choice, how benefit will be assessed, and what alternatives are available. Clarify infusion timing, blood-test checks, fertility or pregnancy precautions, and who to contact outside clinic hours.